Abstract
Background: The phase 2 SUMMIT basket trial (NCT01953926) demonstrated efficacy of neratinib in patients with EGFR exon 18-mutant non-small-cell lung cancer (NSCLC). Here we report the efficacy and safety of neratinib in an expanded subgroup of patients with EGFR exon 18-mutant NSCLC in SUMMIT according to prior EGFR tyrosine kinase inhibitor (TKI) treatment.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
